NIOX Group PLC
NIOX
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
84
Stocks News & Analysis
stocks
Palantir earnings: AI leadership intact; valuation still causes heartburn
Our view of Palantir Technologies.
stocks
As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally
Demand for AI has catapulted tech stocks into the stratosphere.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,051.80 | 38.70 | -0.43% |
| CAC 40 | 8,067.53 | 42.26 | -0.52% |
| DAX 40 | 23,949.11 | 183.30 | -0.76% |
| Dow JONES (US) | 47,085.24 | 251.44 | -0.53% |
| FTSE 100 | 9,714.96 | 13.59 | 0.14% |
| HKSE | 25,735.59 | 216.81 | -0.84% |
| NASDAQ | 23,348.64 | 486.09 | -2.04% |
| Nikkei 225 | 49,104.05 | 2,393.15 | -4.65% |
| NZX 50 Index | 13,586.23 | 19.73 | -0.15% |
| S&P 500 | 6,771.55 | 80.42 | -1.17% |
| S&P/ASX 200 | 8,788.00 | 21.80 | -0.25% |
| SSE Composite Index | 3,947.46 | 12.73 | -0.32% |